Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$50.67M

FY 2025 · Annual

Investing Cash Flow

$7.00M

FY 2025 · Annual

-23.9% YoY

Financing Cash Flow

$5.83M

FY 2025 · Annual

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
Deferred Income Tax(1.68M)0000
Stock-Based Compensation2.62M4.25M4.26M3.94M4.26M
Change in Working Capital(9.88M)(12.5M)(32.09M)39.16M(10.21M)
Accounts Receivables3.39M(4.2M)(13.67M)00
Inventory(6.27M)0000
Accounts Payables(946K)(7.66M)(3.89M)00
Other Working Capital(6.06M)(636K)(10.54M)39.16M(10.21M)
Other Non-Cash Items(1.3M)1.8M(2.24M)(2.53M)(630.52K)
Operating Cash Flow(58.46M)(19.15M)(32.56M)(6.9M)(50.67M)
Capital Expenditures(1.33M)(1.12M)(2.35M)(391K)(134.47K)
Acquisitions (Net)7K0004.8K
Purchases of Investments00000
Sales of Investments03M22.77M9.59M13.51M
Other Investing Activities406K(1K)(1.79M)1K(6.38M)
Investing Cash Flow(917K)1.88M20.63M9.2M7M
Debt Repayment26.63M(2.03M)(2.36M)(8.94M)(8.56M)
Common Stock Issued499K198K395K2.93M14.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities187K198K395K2.93M0
Financing Cash Flow26.82M(1.83M)(1.97M)(6.01M)5.83M
Effect of Forex Changes(483K)(428K)274K(505K)7.41M
Net Change in Cash(33.04M)(19.53M)(13.62M)(4.21M)(30.44M)
Free Cash Flow(59.79M)(20.28M)(34.91M)(7.29M)(50.81M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$49.2M
+ D&A$5.1M
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
- Working Capital-$10.2M
- Other Non-Cash-$630.5K
= Operating Cash Flow-$50.7M
- Capex-$134.5K
= Free Cash Flow-$50.8M

Analysis

FY2025 free cash flow is -$50.8M. FCF conversion is 103.3% of net income. Operating cash flow was -$50.7M, with capex of -$134.5K. The largest bridge item is Working Capital at -$10.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 5, 2026
6-K6-K filingOct 27, 2026
6-K6-K filingOct 21, 2026
6-K6-K filingOct 20, 2026

Does IPHA generate free cash flow?

Innate Pharma S.A. (IPHA) generated -$50.81M of free cash flow in fiscal 2025.

How much operating cash flow does IPHA produce?

Operating cash flow was -$50.67M, before capital expenditures of $134,474.00.